Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00373997 · ClinicalTrials.gov registry record · Phase 4

Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux

A Phase 4 study of Gastroesophageal Reflux and Larynx Disease, sponsored by Vanderbilt University.

Completed
Registry status
Phase 4
Development phase
45
Enrollment target
1
Study location

NCT00373997 is a Phase 4 study of Gastroesophageal Reflux and Larynx Disease that has completed, run by Vanderbilt University. The registered enrollment target is 45 participants, below the 183-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00373997, a Phase 4 study of Gastroesophageal Reflux and Larynx Disease, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
Phase 4
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to determine whether patients with suspected Laryngopharyngeal reflux have inflammation and ultrastructural injury on their laryngeal biopsies.

Interventions

  • PROCEDURE Esophageal and Laryngeal biopsies
  • PROCEDURE egd with biopsy

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410 - Nashville

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2006-09
Est. Completion 2009-12
Phase Phase 4

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT00373997

The ClinicalTrials.gov registry entry for NCT00373997 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (75% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 2 interventions - of which Esophageal and Laryngeal biopsies is the first listed.

NCT00373997 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00373997 about?

NCT00373997 is a clinical study titled "Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux". The purpose of the study is to determine whether patients with suspected Laryngopharyngeal reflux have inflammation and ultrastructural injury on their laryngeal biopsies.

What is the current status of trial NCT00373997?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2006-09. Estimated completion is 2009-12.

What conditions does trial NCT00373997 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux, Larynx Disease.

What interventions are being tested in trial NCT00373997?

The interventions under investigation include: Esophageal and Laryngeal biopsies (PROCEDURE), egd with biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT00373997?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00373997 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroesophageal Reflux

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.